AI Summary
✦ ClarthaAurobindo Pharma is a pharmaceutical company producing generic medicines and active pharmaceutical ingredients globally. Finished formulations, injectables, specialty brands, and APIs drive revenue across CNS, anti-infective, cardiovascular, gastrointestinal, and diabetes therapies. Q1 profit rose 26% to ₹1,033 crore, exceeding expectations and supporting revised estimates. Revenue grew 6.4% year-on-year, while profit increased only 0.5%, indicating limited earnings conversion despite stable margins. ROE is unavailable, and 21.31x debt-to-equity implies substantial leverage that can amplify reported ROE when profitability improves. At 26.1x earnings, valuation appears fair rather than discounted, broadly reflecting current growth. The open question is whether injectable expansion and international execution can improve profit growth without increasing balance-sheet risk.
Price Forecast
Probabilistic Range
Probabilistic lognormal cone using 1Y realized volatility and analyst-target drift when available.
Revenue Forecast
₹ CrEPS Forecast
₹ / shareMulti-factor synthesis of 5 key dimensions
From 28 analysts
Fundamentals
Fundamentals institutional score is 81 using growth durability 81.0.
Valuation
Valuation institutional score is 26 using relative multiple z-scores where peer dispersion is available.
Analyst Consensus
Analyst View institutional score is 47 using mean target upside 0.2%; dispersion penalty 15.2; recommendation breadth from available consensus.
Technical Structure
Technicals institutional score is 49 using EMA-20 continuation within 5% tolerance; VCP range/volume contraction proxy.
Market Sentiment
Recent news flow is balanced or not decisive enough to tilt the tape. Based on 7 recent ticker-linked news items.
Signal Summary
Market intelligence remains Mixed. fundamentals provide support, while valuation and analyst consensus remain considerations.
Composite weights: Fundamentals 25%, Valuation 20%, Analyst Consensus 20%, Technical Structure 20%, Market Sentiment 15%.
Key Data Points
Important Note: This is market intelligence, not investment advice. Always conduct your own research and consider your financial goals and risk tolerance.
Valuation Metrics
Trading 41.3% above historical median. Valuation is rising — currently in the strongly overvalued zone (z-score: +2.42). Confidence: 84%.
Live forward EPS implies next-12-month EPS of ₹92.49. Applying the stock's normalized valuation corridor produces a fair range of ₹1,576.95 to ₹1,905.29, with base value near ₹1,706.44 (+2.9% vs current price).
Live forward estimate anchored to the company's historical valuation corridor.
Forward EPS
₹92.49
Forward P/E
17.9x
Base Fair Value
₹1,706.44
Fair Range
₹1,576.95 - ₹1,905.29
Upside To Base
+2.9%
Estimate Source
Live forward EPS
Growth Estimate
+25.8%
5Y Average
15.30
Current
26.07
Overvalued
20.60
Undervalued
17.05
5Y Average
7.79
Current
13.27
Overvalued
9.69
Undervalued
5.10
5Y Average
1.60
Current
2.73
Overvalued
1.84
Undervalued
1.36
Peers & Comparison
Sector: Health Care · Theme: Pharmaceuticals
| Company | Rev. Growth | Margin | P/E | vs Avg | 52W Perf. |
|---|---|---|---|---|---|
DR. REDDY S LABORATORIES DRREDDYPharmaceuticals | -5.6% | 10.0% | 30.3x Fair | -15% vs avg | -5.0% |
CIPLA LTD CIPLAPharmaceuticals | +3.5% | 12.0% | 35.1x Fair | -1% vs avg | -3.5% |
APOLLO HOSPITALS ENTER. L APOLLOHOSPHospitals & Diagnostic Centres | +18.1% | 7.7% | 65.0x Premium | +83% vs avg | +23.2% |
HINDALCO INDUSTRIES LTD HINDALCOMetals - Aluminium | +32.1% | 5.5% | 14.2x Undervalued | -60% vs avg | +58.0% |
HCL TECHNOLOGIES LTD HCLTECHIT Services & Consulting | +3.0% | 13.0% | 21.3x Undervalued | -40% vs avg | -9.5% |
BAJAJ AUTO LIMITED BAJAJ-AUTOTwo Wheelers | +64.0% | 16.3% | 27.9x Undervalued | -21% vs avg | +42.5% |
EICHER MOTORS LTD EICHERMOTTrucks & Buses | +31.5% | 23.2% | 38.1x Fair | +7% vs avg | +41.0% |
BSE LIMITED BSEStock Exchanges & Ratings | +64.0% | 48.9% | 52.5x Premium | +48% vs avg | +51.8% |
AUROBINDO PHARMA LTD trades at a discount (26.1x vs peer avg 35.5x), suggesting potential undervaluation relative to the Pharmaceuticals cohort. Peers include DR. REDDY S LABORATORIES, CIPLA LTD, APOLLO HOSPITALS ENTER. L — selected based on business model, industry classification, market cap similarity, and business theme alignment.
Financials
Real statement data for revenue, earnings quality, conversion, and balance-sheet coverage. Monetary values are shown in Rs crore.
Latest revenue
₹2.80K CrJun 2026Latest net profit
₹737 CrJun 2026Latest EPS
₹12.69Jun 2026Net margin
32.0%Jun 2026Performance
Bars show revenue and net profit. The line shows net margin.
- Revenue
- Net income
- Net margin %
Earnings
Revenue is shown in crores. EPS is rupees per share.
- Revenue
- EPS
Revenue to profit conversion
Bridge from operating numbers to profit for the latest reported period.
Latest reported period: Jun 2026
Debt level and coverage
Debt, cash and free cash flow compared on the same crore scale.
- Debt
- Free cash flow
- Cash & equivalents
Results
| Metric | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 2,391 | 2,669 | 2,692 | 2,894 | 2,460 | 2,825 | 2,917 | 2,732 | 2,848 | 2,790 | 2,747 | 2,787 | 2,800 |
| Expenses + | 1,968 | 2,124 | 2,210 | 2,119 | 1,961 | 2,104 | 2,203 | 2,135 | 2,052 | 2,065 | 1,958 | 2,005 | 1,917 |
| Operating Profit | 422 | 545 | 482 | 775 | 499 | 721 | 713 | 597 | 796 | 725 | 789 | 781 | 882 |
| OPM % | 18% | 20% | 18% | 27% | 20% | 26% | 24% | 22% | 28% | 26% | 29% | 28% | 32% |
| Other Income + | 113 | 103 | 331 | 123 | 65 | 123 | 54 | 114 | 84 | 160 | 113 | 214 | 242 |
| Interest | 32 | 37 | 61 | 53 | 51 | 52 | 66 | 61 | 60 | 57 | 48 | 47 | 47 |
| Depreciation | 60 | 66 | 64 | 65 | 67 | 68 | 68 | 94 | 70 | 71 | 72 | 72 | 69 |
| Profit before tax | 444 | 546 | 687 | 780 | 446 | 724 | 633 | 556 | 750 | 755 | 782 | 876 | 1,008 |
| Tax % | 24% | 24% | 9% | 26% | 26% | 26% | 25% | 27% | 25% | 23% | 26% | 21% | 27% |
| Net Profit + | 336 | 416 | 624 | 579 | 329 | 538 | 472 | 408 | 559 | 581 | 582 | 692 | 737 |
| EPS in Rs | 5.74 | 7.10 | 10.65 | 9.88 | 5.62 | 9.25 | 8.13 | 7.03 | 9.63 | 10.01 | 10.02 | 11.92 | 12.69 |
| Raw PDF | |||||||||||||
| YOY Sales Growth % | 37.27% | 36.99% | 14.03% | 20.27% | 2.90% | 5.84% | 8.34% | -5.60% | 15.78% | -1.23% | -5.81% | 2.00% | -1.71% |
| Material Cost % | 57.49% | 56.47% | 58.00% | 48.56% | 52.69% | 49.91% | 50.20% | 52.62% | 48.90% | 49.02% | 46.84% | 47.05% | 44.32% |
| Employee Cost % | 9.87% | 9.27% | 9.22% | 8.60% | 10.54% | 9.40% | 9.09% | 10.00% | 9.94% | 10.55% | 10.60% | 10.50% | 10.57% |
| Exceptional items | 18 | 36 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -17 | 0 | 0 |
| Other income normal | 95 | 67 | 331 | 123 | 65 | 123 | 54 | 114 | 84 | 160 | 130 | 214 | 242 |
| Exceptional items AT | 18 | 36 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -13 | 0 | 0 |
| Profit excl Excep | 318 | 380 | 624 | 579 | 329 | 538 | 472 | 408 | 559 | 581 | 595 | 692 | 737 |
| Profit for PE | 318 | 380 | 624 | 579 | 329 | 538 | 472 | 408 | 559 | 581 | 595 | 692 | 737 |
| Profit for EPS | 336 | 416 | 624 | 579 | 329 | 538 | 472 | 408 | 559 | 581 | 582 | 692 | 737 |
| YOY Profit Growth % | 161% | 106% | 93% | -3% | 3% | 42% | -24% | -29% | 70% | 8% | 26% | 70% | 32% |
All values in ₹ Crores unless otherwise stated. Source: Screener Master (Standalone).
Events Timeline
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation